The Effects of Calcium Channel Blockers in the Prevention of Stroke in Adults with Hypertension: A Meta-Analysis of Data from 273,543 Participants in 31 Randomized Controlled Trials

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Chen, Gui Jv ^a   Yang, Mao Sheng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; ISRADIPINE; LACIDIPINE; NICARDIPINE; NIFEDIPINE; PLACEBO; TRICHLORMETHIAZIDE; VERAPAMIL;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CONFIDENCE INTERVALS; DIURETICS; HUMANS; HYPERTENSION; MIDDLE AGED; ODDS RATIO; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84874642897     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057854     Document Type: Article

References (40)

1. Hamilton M, Thompson EM, Wisniewski TK, (1964) The role of blood-pressure control in preventing complications of hypertension. Lancet 1: 235-238.
2. Liu GT, Zeng GM, Hong X, (2011) Long-term calcium channel blockers: The best choice of antihypertensive treatment for the Chinese hypertensive population. Zhongguo She Qu Yi Shi 13: 10-11 (in Chinese).
3. National Intervention Cooperative Study in Elderly Hypertensives Study Group (1999) Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 34: 1129-1133.
4. Song YY, Yang YL, (2011) Antihypertensive effect of levamlodipine besylate and enalapril in the patients with cerebrovascular disorder. Zhongguo Lao Nian Xue Za Zhi 31: 4039-4040 (in Chinese).
5. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, et al. (2000) Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356: 359-365.
6. Hill AB, (1966) Reflections on controlled trial. Ann Rheum Dis 25: 107-113.
7. Hill AB, (1965) The Environment and Disease: Association or Causation? Proc R Soc Med 58: 295-300.
8. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
9. Colditz GA, Burdick E, Mosteller F, (1995) Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am J Epidemiol 142: 371-382.
10. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
11. Deeks JJ, (2001) Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 323: 157-162.
12. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, et al. (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757-764.
13. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, et al. (1998) Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21: 597-603.
14. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA, (2005) ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators.Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 23: 641-648.
15. Liu L, Wang JG, Gong L, Liu G, Staessen JA, (1998) Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 16: 1823-1829.
16. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, et al. (2004) Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 364: 849-857.
17. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, et al. (2010) ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9: 469-480.
18. Ekbom T, Linjer E, Hedner T, Lanke J, De Faire U, et al. (2004) Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. Blood Press 13: 137-141.
19. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, et al. (2005) ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366: 895-906.
20. Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, et al. (2006) Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48: 374-384.
21. Liu L, Zhang Y, Liu G, Li W, Zhang X, et al. (2005) FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 23: 2157-2172.
22. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, et al. (2002) European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106: 2422-2427.
23. Turnbull F, (2003) Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362: 1527-1535.
24. Wang YZ, Chen W, Cui FQ, (1998) Effect of calcium antagonists on the secondary prevention of essential hypertension. Zhongguo Man Xing Bing Yu Fang Yu Kong Zhi 6: 235-238 (in Chinese).
25. Dens JA, Desmet WJ, Coussement P, De Scheerder IK, Kostopoulos K, et al. (2001) Usefulness of Nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). Nisoldipine in Coronary artery disease in Leuven. Am J Cardiol 87: 28-33.
26. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, et al. (1996) Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 14: 1237-1245.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997.
28. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, et al. (2003) CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289: 2073-2082.
29. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, et al. (1999) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354: 1751-1756.
30. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, et al. (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356: 366-372.
31. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, et al. (2003) INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290: 2805-2816.
32. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, et al. (1996) Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 276: 785-791.
33. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, et al. (2003) Shell Investigators. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 12: 160-167.
34. Zanchetti A, Rosei EA, Dal Palù C, Leonetti G, Magnani B, et al. (1998) The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 16: 1667-1676.
35. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, et al. (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338: 645-652.
36. Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, et al. (2003) CASE-J Study Group. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 26: 979-990.
37. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, et al. (2003) Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138: 542-549.
38. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, et al. (1999) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 340: 677-684.
39. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, et al. (2005) MOSES Study Group. Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218-1226.
40. Donovan AL, Flexman AM, Gelb AW, (2012) Blood pressure management in stroke. Curr Opin Anaesthesiol 25: 516-522.